American Society of Hirudotherapy

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014) · Microsurgery · n=23

Observational study: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCohort / case seriesCondition: Breast Reconstruction Flap Salvage →

Study Profile

Design
single-center, retrospective cohort study using a prospectively maintained institutional database (University of Pennsylvania, Division of Plastic Surgery)
Sample size (n)
23
Intervention
Medicinal leech therapy for surgically uncorrectable venous congestion after free flap breast reconstruction (n=4 surgically uncorrectable cases)
Main result
Among 4 leech-treated patients: 1 flap partially salvaged, 3 flaps completely lost (75% total loss vs 42.1% in non-leeched comparator group, p=0.32 non-significant); leech patients had lower hemoglobin nadirs and received more blood transfusions; length of stay 8.0 ± 3.6 days (leech) vs 6.5 ± 2.1 days (non-leech), p=0.43
Follow-up duration
post-operative inpatient stay through discharge

Key Findings

  • Cautionary US data: in surgically uncorrectable venous congestion after free-flap breast reconstruction, 75% of leech-treated flaps were completely lost
  • Leech-treated patients had significantly lower hemoglobin nadirs and higher transfusion requirements than non-leech comparator group
  • Authors concluded that when venous congestion cannot be surgically corrected, total flap removal may be a better option than attempted leech salvage
  • Differences in salvage and length-of-stay were not statistically significant (p=0.32 and p=0.43) due to very small sample (n=4 leech group)
  • Important counterweight to optimistic single-center German and Italian leech-salvage data in the broader breast-reconstruction literature

Limitations

  • Very small leech-treated subgroup (n=4) - severely underpowered for statistical comparison
  • Retrospective design with confounding by indication (only surgically uncorrectable cases received leeches)
  • Single US center, single anatomical site (breast) - findings may not generalize to other free-flap locations
  • No assessor blinding; salvage outcome relied on clinical judgment of attending surgeon
  • No long-term follow-up on aesthetic outcome or revisional surgery requirements

Clinical Implications

Pannucci 2014 provides important cautionary data that should be presented alongside the more optimistic flap-salvage literature. In free-flap breast reconstruction with surgically uncorrectable venous congestion, the published US experience suggests that leech therapy may not salvage most cases and that early decision-making to abandon the flap may be preferable to prolonged unsuccessful salvage attempts. For US clinicians considering leech therapy in this setting, Pannucci 2014 supports honest informed consent that includes the realistic probability of total flap loss despite leech application, particularly in surgically uncorrectable cases.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.